Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis

European Journal of Haematology

Volumn 79, Issue 6, 2007, Pages 494-500

  Han, Sai ^a   Chong, Victor ^b   Murray, Tom ^b   McDonagh, Theresa ^c   Hunter, John ^d   Poon, Fat Wui ^a   Gray, Henry W ^a   Neilly, James B ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

99mTc Aprotinin; Amyloidosis; Scintigraphy

Indexed keywords

APROTININ PERTECHNETIC ACID TC 99M; PERTECHNETIC ACID TC 99M; UNCLASSIFIED DRUG; APROTININ; TECHNETIUM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMYLOIDOSIS; ARTICLE; BLADDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEART AMYLOIDOSIS; HUMAN; HUMAN TISSUE; KIDNEY; LEG; LIVER; MALE; PRIORITY JOURNAL; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBCUTANEOUS TISSUE; URINARY TRACT; WHOLE BODY SCINTISCANNING; BIOPSY; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; APROTININ; BIOPSY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 36249010400     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00963.x     Document Type: Article

References (16)

1. Falk RH, Comenzo RL, Skinner Ml. The systemic amyloidoses. N Engl J Med 1997 337 : 898 909.
2. Merlini G, Westermark P. The systemic amyloidosis: clear understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004 255 : 159 78.
3. Bird J, Cavenagh J, Hawkins P, et al. "Guidelines on the Diagnosis and Management of AL Amyloidosis" by the British Committee for Standards in Haematology in conjunction with Working Group of the UK Myeloma Forum. Br J Haematol 2004 125 : 681 700.
4. Hawkins PN, Levender P, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with I-123 - labelled serum amyloid P component. N Engl J Med 1990 325 : 508 13.
5. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995 22 : 1393 401.
6. Joint Formulary Committee. British National Formulary, 52nd edn. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006.
7. Bayer Healthcare. Prescribing Information on Trasylol [WWW document]. URL http://www.univgraph.com/bayer/inserts/trasylol.pdf [accessed on 10 October 2007].
8. Dollery C, ed. Therapeutic Drugs: Aprotinin. 2nd edn. Edinburgh : Churchill Livingston, 1999.
9. Cardoso I, Pereira PJ, Damas AM, Saraiva MJ. Aprotinin binding to amyloid fibrils. Eur J Biochem 2000 267 : 2307 11.
10. 99mTc-Aprotinin scintigraphy in amyloidosis. J Nucl Med 2003 44 : 177 83.
11. Wald DS, Gray HH. Restrictive cardiomyopathy in systemic amyloidosis. Q J Med 2003 96 : 380 2.
12. 99mTc aprotinin. Nucl Med Commun 2005 26 : 535 9.
13. Administration of Radioactive Substances Advisory Committee (ARSAC) : Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. December 1998.
14. Azzoni AR, Kusnadi AR, Miranda EA, Nikolov ZL. Recombinant aprotinin produced in transgenic corn seed: extraction and purification studies. Biotechnol Bioeng 2002 80 : 268 76.
15. Day J, et al. Effect of aprotinin and recombinant variants on platelet protease-activated receptor1 activation. Ann Thorac Surg 2006 81 : 619 24.
16. Arndt JW, Grootscholten MI, Van Hogezand RA, Griffioen G, et al. Inflammatory Bowel Disease Activity Assessment using Technetium 99m HMPAO leukocytes. Dig Dis Sci 1997 42 : 387 93.